-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Overcoming the Barrier of TP53 Dysfunction to Cure Blood Cancers

PhD Trainee
Program: Special Scientific Symposia
Sunday, December 6, 2015: 7:30 AM-9:00 AM
Hall E1, Level 2 (Orange County Convention Center)
Chair:
Andrew W. Roberts, MBBS, PhD, Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital

Disclosures:
Roberts: Genentech: Other: The Walter and Eliza Hall Institute receives milestone payments for the development of venetoclax , Research Funding ; AbbVie: Other: The Walter and Eliza Hall Institute receives milestone payments for the development of venetoclax , Research Funding .

Laura D. Attardi, PhD1*, Kathryn Bieging-Rolett2*, Stephano Spano Mello2*, Elizabeth Valente2*, Colleen A. Brady2* and Dadi Jiang2*

1Departments of Radiation Oncology and Genetics, Stanford University School of Medicine, Stanford, CA
2Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA

Guillermina Lozano, PhD

Genetics, University of Texas M.D. Anderson Cancer Center, Houston, TX

David C.S. Huang, MBBS, MRCP, PhD

Walter & Eliza Hall Institute of Medical Research, Parkville, Australia